EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor

Vito Terlizzi iD, Miquéias Lopes-Pacheco

Therapeutic Advances in Respiratory Disease · 2025-01 · 19

DOI: 10.1177/17534666251323194 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Respiratory Disease, online erschienen am 31.03.2025. Verfasst von Vito Terlizzi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Medicine, Cystic Fibrosis Regional Reference Center, Meyer Children's Hospital IRCCS, Viale Gaetano Pieraccini 24, Florence, …. Hauptthemen laut MEDLINE: Cystic Fibrosis, Aminophenols, Quinolones, Cystic Fibrosis Transmembrane Conductance Regulator. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 175 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over the past decade, major clinical advances have been made in the healthcare and therapeutic development for cystic fibrosis (CF), a lethal genetic disease caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR) protein. CFTR modulators represent innovative treatments that directly target the primary defects in the mutated CFTR protein and have demonstrated significant clinical benefits for many people with CF (pwCF) who are eligible for these treatments. In particular, the triple combination therapy composed of elexacaftor, tezacaftor, and ivacaftor (ETI) has changed the CF therapeutic landscape by significantly improving lung function, quality of life, and predicted survival rates. Here, we provided a comprehensive summary of the impact of ETI on clinical outcomes and the need for further research on long-term efficacy, side effects, pregnancy, possible drug–drug interactions, and extra-pulmonary manifestations. Moreover, a significant number of pwCF are unresponsive to these drugs or cannot afford their high costs. We, therefore, discussed health inequity issues and alternative therapeutic strategies under development aiming to obtain effective therapies for all pwCF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisAminophenolsQuinolonesCystic Fibrosis Transmembrane Conductance RegulatorBenzodioxolesChloride Channel AgonistsIndolesPyridinesPyrazolesPyrrolidinesHumansDrug CombinationsTreatment OutcomeMutationQuality of LifeDrug InteractionsQuinolines

Stichwörter der Autor:innen

CFTR modulatorefficacyhealth inequityoutcomessafetytherapy development

Substanzen

AminophenolsQuinolonesCystic Fibrosis Transmembrane Conductance RegulatorBenzodioxolesDrug CombinationsChloride Channel AgonistsCFTR protein, humanIndolesivacaftorPyridines

Autor:innen und Institutionen

  • Department of Pediatric Medicine, Cystic Fibrosis Regional Reference Center, Meyer Children's Hospital IRCCS, Viale Gaetano Pieraccini 24, Florence, Italy.
  • Department of Pediatrics, Cystic Fibrosis and Airway Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.

ORCID-Profile: Vito Terlizzi

Zitieren

APA

Terlizzi, V., & Lopes-Pacheco, M. (2025). Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor. Therapeutic Advances in Respiratory Disease, 19. https://doi.org/10.1177/17534666251323194

Vancouver

Terlizzi V, Lopes-Pacheco M. Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor. Therapeutic Advances in Respiratory Disease. 2025;19. doi:10.1177/17534666251323194

BibTeX
@article{Terlizzi2025,
  author = {Terlizzi, Vito and Lopes-Pacheco, Miquéias},
  title = {Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor},
  journal = {Therapeutic Advances in Respiratory Disease},
  year = {2025},
  volume = {19},
  doi = {10.1177/17534666251323194}
}
Kostenlos starten →